An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease.
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms SHIELD-3
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2014 Status changed from suspended to discontinued according to ClinicalTrials.gov record.
- 23 Aug 2013 Status changed from recruiting to suspended, according to a GlaxoSmithKline media release. New recruitment and dosing has been suspended pending further review.